All Posts

Effect of PCC on Bleeding Patients with FXa Inhibitor

Click here for a current study report on PCC therapy in patients with FXa inhibitors who are bleeding or needing surgery: Shaw JR, Gray H, Xu Y, et al. Effect of PCC on thrombin generation in patients on FXaI with bleeding or needing urgent surgery (GAUGE). Blood Adv. 2026;10(15):5378–88. doi: 10.1182/bloodadvances.2026020203. PMID: 42275536; PMCID: PMC13452292. […]

Bleeding Disorders

ISTH Paris Summary

Thanks to Dr. Ali Sadeghi-Khomami, PBI Research Scientist, for this downloadable comprehensive summary of the ISTH meeting in Paris.

Events and Conferences: Bleeding Disorders Conference August 13–15

Thanks to Elaine Benoit, PBI’s marketing guru, for recent updates to our Events and Conferences Calendar. This week is the NBDF’s Bleeding Disorders Conference in Orlando, FL, USA, August 13–15. It’s not too late to register. Our colleagues at George King Bio-Medical will exhibit at booth 100. If you don’t see your hemostasis-related event or […]

LinkedIn Post: FXIII Deficiency Assays

Click here for a provocative LinkedIn “Blood Doctor” post by Dr. Abdul Mannan that describes the time-honored clot solubility test and the quantitative chromogenic assay for FXIII deficiency.

Letter to STH: AI Models for Viscoelastic Assays

Click here for a summary of a letter to the STH editor: Yeong JK, Panigada M, Altememi MA, Favaloro EJ, Fan BE. Large language models for viscoelastic tests: a head-to-head evaluation of ChatGPT, Gemini, and DeepSeek for thromboelastography and ROTEM interpretation. Semin Thromb Hemost. 2026. doi: 10.1055/a-2918-4009. PMID: 42520817. In addition, click here for a […]

Global Hemostasis Assays

Review: AI Designing the Future of Hemostasis

Check your medical library for this review article on AI-based peptide design to modify the GPIbα-VWF interaction in platelet-type von Willebrand disease: Kazmirchuk TDD, Wang J, Corbette J, et al. Designing the future of hemostasis. Semin Thromb Hemost. 2026 Jun 9. doi: 10.1055/a-2885-4368. PMID: 42225137. Abstract Bleeding disorders arising from dysfunctional platelet-protein interactions pose a […]

Bleeding Disorders

August 2026 Cheat Sheet

Click the Cheat Sheet for your August 2026 edition. You can also request your personal Cheat Sheet with links to recent Fritsma Factor entries by completing the “Sign Up” entry on the right. Fritsma Factor Posts, Educational Modules, and Resources are provided compliments of Precision BioLogic, Affinity Biologicals, and George King Bio-Medical. We welcome your […]

Better Managed Anticoagulation

Click Edward Lee Carter, BSPharm BPP‘s Better Calibrated Anticoagulation LinkedIn summary from the recent ISTH meeting that describes the need for managing the risks of anticoagulant therapy through lab measurement and monitoring outcomes.

Anticoagulant Therapy

August 2025 QQ: Coagulation Control Proteins

Our August 2026 Quick Question is a simple quiz that asks, “Which is NOT an endogenous coag control protein?” This is your opportunity to review the plasma-based coagulation mechanism and recall the functions of the control proteins, available in our Educational Module entitled Coagulation Overview. One of these is NOT an endogenous control protein for […]

Quick Question Archive

July 2026 QQ Summary: VWD Therapeutic

Our July 2026 QQ asked: What VWD therapeutic is NOT a replacement factor? Our 24 participants responded… Desmopressin: 18 (75%) Humate P: 1 (4%) Vonvendi: 4 (17%) Wilate: 1 (4%) VWD bleeding is first managed by applying “PRICE:” protection, rest, ice, compression, and elevation. Next, desmopressin (DDAVP) is administered via injection, infusion, and, in Europe, […]

Quick Question Archive

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question